Latest Advances in Lung Cancer Research

FDA fast-tracks ZL-1310, a promising targeted therapy showing 74% response rate in advanced small cell lung cancer patients with limited treatment options.

New AI model Sybil predicts future lung cancer risk from a single CT scan, offering hope for personalized screening, especially for Asian never-smokers.

AbbVie’s Emrelis, an FDA-approved drug, targets c-Met proteins in NSCLC for effective cancer treatment, marking significant advancements in antibody-drug conjugates (ADCs).

A major Australian-Canadian lung cancer screening study found that 73% of high-risk participants had incidental findings during baseline CT scans, with 10% requiring clinical follow-up, highlighting significant inconsistencies in how these findings are reported to doctors and raising important questions about standardization as Australia prepares to launch its national screening program in 2025.

Leading lung cancer specialists discuss revolutionary advances in treating EGFR-mutated non-small cell lung cancer, highlighting how new combination therapies like amivantamab plus chemotherapy are doubling progression-free survival and offering hope for patients with challenging complications like leptomeningeal metastases, while emphasizing practical strategies for managing treatment side effects in community practice.

Chest CT scans used for lung cancer screening can do more than just find early lung cancer. These scans can also detect heart problems and early emphysema, offering a three-in-one health check for people at risk.

Oncologists have discovered that difficulties treating and managing the most common type of lung cancer, adenocarcinoma or non-small cell lung cancer, is related to a protein called agrin.

A study of over 10,000 people showed that sticking with regular lung cancer screening leads to better detection of early-stage cancer. However, fewer people returned for follow-up screenings each year.

Researchers at Johns Hopkins Medicine have developed an innovative computer model that could significantly improve immunotherapy outcomes for lung cancer patients.

A new JAMA review shows that small cell lung cancer, which affects 95% smokers and has only 12-30% five-year survival, is seeing breakthrough improvements with immunotherapy extending survival to 56 months for early-stage disease, though advanced cases remain challenging with most patients relapsing within three months.

The study highlights that the timing of irAEs depends on the specific immunotherapy and recent treatment history.

New research separates the effects of smoking, environment, genetics, and healthcare access on lung cancer mortality, providing insights for better prevention strategies.